Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Biogen Idec
(NQ:
BIIB
)
185.41
-1.50 (-0.80%)
Streaming Delayed Price
Updated: 3:50 PM EST, Jan 8, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Biogen Idec
< Previous
1
2
...
11
12
13
14
15
16
17
18
19
...
57
58
Next >
BIOGEN ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Biogen Inc. and Encourages Investors to Contact the Firm
May 24, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
Stockholder Alert: Robbins LLP Informs Investors that a Shareholder Has Filed a Class Action Against Biogen Inc. (BIIB)
May 24, 2024
From
Robbins LLP
Via
GlobeNewswire
BIOGEN INC. (NASDAQ: BIIB) INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Biogen Inc.
May 24, 2024
From
Bernstein Liebhard LLP
Via
GlobeNewswire
Deep Dive Into Biogen Stock: Analyst Perspectives (17 Ratings)
↗
May 22, 2024
Via
Benzinga
How Is The Market Feeling About Biogen?
↗
May 20, 2024
Via
Benzinga
Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Biogen Inc. (BIIB) Investors
May 23, 2024
From
Kirby McInerney LLP
Via
Business Wire
BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
May 23, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Biogen Inc. with Losses to Contact the Firm
May 23, 2024
From
Schall Law
Via
GlobeNewswire
The Analyst Landscape: 27 Takes On Biogen
↗
April 29, 2024
Via
Benzinga
Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week
↗
April 29, 2024
With the earnings season now halfway through, the percentage of S&P 500 companies reporting positive earnings surprises and the magnitude of earnings surprises were above their 10-year averages.
Via
Benzinga
Topics
Stocks
These Analysts Revise Their Forecasts On Biogen After Q1 Results
↗
April 25, 2024
Via
Benzinga
BIIB INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
May 23, 2024
From
Robbins Geller Rudman & Dowd LLP
Via
Business Wire
Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences
May 22, 2024
From
Biogen Inc.
Via
GlobeNewswire
Larimar Therapeutics' Friedreich's Ataxia Investigational Drug Differentiated From Biogen's Marketed Drug
↗
May 21, 2024
Larimar Therapeutics announces FDA lift of partial clinical hold on nomlabofusp (CTI-1601) for Friedreich's Ataxia. Data from Phase 2 study shows well-tolerated treatment with significant frataxin...
Via
Benzinga
Large Cap Biopharmaceuticals Performance
↗
May 20, 2024
The biotech sector remains a laggard YTD as can be seen by the IBB.
Via
Talk Markets
Wall Street Favorites: 3 Biotech Stocks with Strong Buy Ratings for May 2024
↗
May 17, 2024
With new innovation, millions of retiring baby boomers, and an increase in mergers, biotech stocks to buy have a good deal of upside ahead.
Via
InvestorPlace
Tale Of Two Ionis-Partnered Neurology-Focused Early Stage Assets-Biogen Discontinues One, Decides Not To Exercise Licensing Option For Another
↗
May 16, 2024
Ionis Pharmaceuticals and Biogen have halted development of BIIB105 for ALS after Phase 1/2 study results showed no impact on key clinical outcomes.
Via
Benzinga
Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis
May 16, 2024
From
Biogen Inc.
Via
GlobeNewswire
Biogen Stock Continues Its 20% Sprint On A Twist In Alzheimer's Treatment
↗
May 15, 2024
The company is hoping to launch an under-the-skin version of its infusion, Leqembi.
Via
Investor's Business Daily
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Under the Fast Track Status
May 14, 2024
From
Biogen Inc.
Via
GlobeNewswire
Jim Cramer Likes Micron And Its CEO, Recommends Buying This Big Bank
↗
May 13, 2024
Jim Cramer recommends buying Micron, adding that he likes the company's CEO Sanjay Mehrotra. As for Fidelis? "Not a favorite."
Via
Benzinga
3 S&P 500 Stocks to Rival Nvidia’s 2023 Performance in the Second Half of 2024
↗
May 11, 2024
Let’s explore three stocks that are well-positioned to rival Nvidia’s growth rates in the second half of 2024.
Via
InvestorPlace
Topics
Stocks
The 3 Most Undervalued Pharma Stocks to Buy in May 2024
↗
May 09, 2024
Investors looking for good deals in the pharmaceutical industry should watch out for these three undervalued pharma stocks.
Via
InvestorPlace
Why Is Nuvo Group (NUVO) Stock Up 200% Today?
↗
May 06, 2024
Although prenatal care specialist Nuvo Group saw its shares soar on Monday, NUVO stock faces skepticism over its SPAC merger.
Via
InvestorPlace
Biogen Reports Progress on Corporate Responsibility Priorities
May 02, 2024
From
Biogen Inc.
Via
GlobeNewswire
7 Retirement Stocks to Buy at a 52-Week Low in April
↗
April 29, 2024
One of the best ways to keep your portfolio safe while generating income is with dividend-paying retirement stocks at 52-week lows.
Via
InvestorPlace
Topics
Retirement
Stock Market Rebounds; Tesla, Microsoft, Google, Meta, Chipotle, GE In Focus: Weekly Review
↗
April 26, 2024
Microsoft, Tesla, Google, GE and Chipotle were earnings winners. Meta was a notable loser.
Via
Investor's Business Daily
Meta Platforms To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Thursday
↗
April 25, 2024
Via
Benzinga
Why Biogen Stock Leaped Nearly 5% Higher Today
↗
April 24, 2024
The company came out swinging with its first set of quarterly earnings for this year.
Via
The Motley Fool
Biogen/Eisai's Popular Alzheimer's Drug Leqembi Is Seeing Slow Adoption - Here's Why
↗
April 24, 2024
Discover the challenges facing Leqembi, the first Alzheimer's drug shown to slow progression. Skepticism among doctors and concerns about efficacy and costs hinder widespread adoption despite FDA...
Via
Benzinga
< Previous
1
2
...
11
12
13
14
15
16
17
18
19
...
57
58
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
